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A bs tr ac t
Background
The safety of drug-eluting stents has been called into question by recent reports of 
increased stent thrombosis, myocardial infarction, and death. Such studies have been 
inconclusive because of their insufficient size, the use of historical controls, a limited 
duration of follow-up, and a lack of access to original source data.
Methods
We performed a pooled analysis of data from four double-blind trials in which 1748 
patients were randomly assigned to receive either sirolimus-eluting stents or bare-
metal stents and five double-blind trials in which 3513 patients were randomly as-
signed to receive either paclitaxel-eluting stents or bare-metal stents; we then ana-
lyzed the major clinical end points of the trials.
Results
The 4-year rates of stent thrombosis were 1.2% in the sirolimus-stent group versus 
0.6% in the bare-metal–stent group (P = 0.20) and 1.3% in the paclitaxel-stent group 
versus 0.9% in the bare-metal–stent group (P = 0.30). However, after 1 year, there 
were five episodes of stent thrombosis in patients with sirolimus-eluting stents versus 
none in patients with bare-metal stents (P = 0.025) and nine episodes in patients with 
paclitaxel-eluting stents versus two in patients with bare-metal stents (P = 0.028). 
The 4-year rates of target-lesion revascularization were markedly reduced in both 
the sirolimus-stent group and the paclitaxel-stent group, as compared with the 
bare-metal–stent groups. The rates of death or myocardial infarction did not differ 
significantly between the groups with drug-eluting stents and those with bare-metal 
stents.
Conclusions
Stent thrombosis after 1 year was more common with both sirolimus-eluting stents 
and paclitaxel-eluting stents than with bare-metal stents. Both drug-eluting stents 
were associated with a marked reduction in target-lesion revascularization. There were 
no significant differences in the cumulative rates of death or myocardial infarction 
at 4 years.
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By reducing neointimal hyperplasia after vascular injury, drug-eluting coronary-artery stents decrease late luminal loss (the 
difference between the minimal luminal diame-
ter immediately after the procedure and the diam-
eter at 6 months) and angiographic restenosis, as 
compared with bare-metal stents. This decrease, 
in turn, reduces the need for subsequent revascu-
larization procedures.1-9 Despite these benefits, 
drug-eluting stents may engender adverse arterial 
responses, including delayed endothelialization 
and hypersensitivity to the polymeric coating that 
regulates drug dose and release kinetics.10-13 Re-
cent reports from randomized trials and obser-
vational studies using historical controls have sug-
gested that drug-eluting stents may be associated 
with increased rates of late stent thrombosis and 
death, as compared with bare-metal stents.14-17 
These studies have been inconclusive, however, 
because of an insufficient number of patients, the 
absence of concurrent controls, a limited duration 
of follow-up, and a lack of access to original source 
data. Since more than 1 million of these perma-
nent bioactive devices are implanted in patients 
annually, understanding the relative safety and ef-
ficacy of drug-eluting stents represents a major 
public health imperative.
To address the limitations of previous stud-
ies, we performed a pooled analysis of data from 
four double-blind trials in which patients were 
randomly assigned to receive polymer-based siro-
limus-eluting stents or bare-metal stents and five 
double-blind trials in which patients were randomly 
assigned to receive polymer-based paclitaxel-elut-
ing stents or bare-metal stents. We report on the 
safety and efficacy of drug-eluting stents with 
4-year follow-up after device implantation.
Me thods
Study Description
The databases from four prospective, multicenter, 
double-blind, placebo-controlled randomized tri-
als of sirolimus-eluting stents versus bare-metal 
stents were obtained from Cordis. These trials were 
the Randomized Study with the Sirolimus-Coat-
ed Bx Velocity Balloon-Expandable Stent in the 
Treatment of Patients with De Novo Native Cor-
onary-Artery Lesions (RAVEL), the Sirolimus-Elut-
ing Balloon-Expandable Stent in the Treatment of 
Patients with De Novo Native Coronary-Artery Le-
sions (SIRIUS), and the smaller European and Lat-
in American (E-SIRIUS) and Canadian (C-SIRIUS) 
trials.1-4 Similarly, the databases from five pro-
spective, multicenter, double-blind, placebo-con-
trolled, randomized trials of paclitaxel-eluting 
stents versus bare-metal stents were obtained from 
Boston Scientific. These trials consisted of the 
studies TAXUS-I, TAXUS-II, TAXUS-IV, TAXUS-V, 
and TAXUS-VI.5-9 These specific trials were se-
lected because they are the only double-blind tri-
als that compared each of the drug-eluting stents 
with bare-metal controls and that also served as 
the basis for the approval of the drug-eluting stents 
in the United States and Europe. In both cases, 
permission was obtained for the performance of 
an unrestricted, patient-level pooled analysis.
Details of the design and conduct of each of 
the trials included in these analyses have been re-
ported previously.1-9 In each trial, patients with a 
single previously untreated native coronary-artery 
lesion were prospectively and randomly assigned 
in equal proportion to receive either a drug-elut-
ing stent or an otherwise equivalent bare-metal 
stent. Entry criteria, device specifications, and geo-
graphic location varied somewhat, as outlined in 
Table 1. At the time of this report, the patients, 
investigators, study personnel, and sponsors were 
still unaware of assignments to study groups, 
with follow-up continuing to 5 years. Data regard-
ing the use of aspirin and a thienopyridine were 
not consistently captured during follow-up. How-
ever, data on the use of antiplatelet drugs at the 
time of late thrombosis associated with drug-elut-
ing stents were obtained from the manufacturers 
of both drug-eluting stents. No agreements with 
the sponsors regarding data confidentiality exist.
End Points and Definitions
The goals of our study were to determine the 
short-term and long-term safety and efficacy of 
drug-eluting stents as compared with bare-metal 
stents. Before receiving the study databases, we 
specified that we would examine the following 
end points: stent thrombosis, as defined in the 
study protocols (see the Supplementary Appen-
dix, available with the full text of this article at 
www.nejm.org)1-9; revascularization of the target 
lesion or target vessel; any myocardial infarction 
and Q-wave and non–Q-wave myocardial infarc-
tion; death from any cause and from cardiac and 
noncardiac causes; composite death or myocar-
dial infarction; composite death or Q-wave myo-
cardial infarction; and composite death from car-
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diac causes or myocardial infarction. The following 
time periods were prespecified for analysis of 
event rates: the time from stent implantation un-
til 30 days after implantation, from 30 days after 
implantation until the latest follow-up, from 30 
days after implantation until 1 year, from 1 year 
after implantation until the latest follow-up, and 
from the time of stent implantation until the lat-
est follow-up.
We used data from the original databases, as 
defined and adjudicated by the clinical events 
committees for each study, in our analysis.1-9 Since 
the individual adverse-event narratives and orig-
inal source documents were not available to us, 
readjudication of individual events to accommo-
date common definitions was not possible.
Statistical Analysis
We compared categorical variables by the chi-
square test or Fisher’s exact test. Continuous vari-
ables are described as means (±SD) and were com-
pared by means of unpaired t-tests. At the time of 
this report, we had access to 5-year data from 
RAVEL and TAXUS-I; 4-year data from SIRIUS, 
E-SIRIUS, C-SIRIUS, TAXUS-II, and TAXUS-IV; 
3-year data from TAXUS-VI; and 2-year data from 
TAXUS-V. We used Kaplan–Meier time-to-event 
estimates for the primary analyses, which were 
compared with the log-rank or exact log-rank test. 
Analyses were truncated at 4 years of follow-up 
owing to the small number of patients with data 
thereafter. We included data from all patients that 
were analyzed in each of the original study reports 
in our analysis, with follow-up data censored at 
the time of first event (for each specific event curve) 
or latest known follow-up. The Breslow–Day test 
for heterogeneity demonstrated that trials involv-
ing sirolimus-eluting stents and paclitaxel-eluting 
stents were sufficiently homogeneous to justify the 
pooled analyses performed. All P values are two-
sided.
R esult s
Patients
A total of 1748 patients were randomly assigned 
to study groups and underwent percutaneous coro-
nary intervention in the RAVEL and three SIRIUS 
trials comparing sirolimus-eluting stents with 
bare-metal stents (the sirolimus-stent trials). An-
other 3513 patients were randomly assigned to 
study groups and underwent percutaneous coro-
nary intervention in the five TAXUS trials com-
paring paclitaxel-eluting stents with bare-metal 
stents (the paclitaxel-stent trials). The baseline de-
mographic, procedural, and angiographic charac-
teristics of the patients were well matched in both 
sets of trials (Table 2), except that in the sirolimus-
stent trials, diabetes was slightly more prevalent 
among patients who received bare-metal stents 
than among those who received sirolimus-eluting 
stents. The lengths of lesions and total implanted 
stents were both greater in the paclitaxel-stent 
trials than in the sirolimus-stent trials (reflecting 
varying criteria for trial entry), although more 
stents per patient were used in the sirolimus-
stent trials. Baseline reference measures of ves-
sel diameter and lesion severity were similar for 
stenoses treated with both types of drug-elut-
ing stents and for those treated with bare-metal 
stents.
Stent Thrombosis
From stent implantation through 4-year follow-
up, the rates of stent thrombosis among patients 
with sirolimus-eluting stents did not differ sig-
nificantly from those with bare-metal stents (1.2% 
and 0.6%, respectively; P = 0.20) (Table 3 and Fig. 
1 and 2). Similarly, there were no significant dif-
ferences in the 4-year cumulative rates of stent 
thrombosis between patients with paclitaxel-elut-
ing stents and those with bare-metal stents (1.3% 
and 0.9%, respectively; P = 0.30). However, between 
1 and 4 years, the rates of stent thrombosis in the 
sirolimus-stent group and the bare-metal–stent 
group were 0.6% versus none (P = 0.025, consistent 
with one extra event per 489 patient-years); dur-
ing the same period, the rates in the paclitaxel-
stent group and the bare-metal–stent group were 
0.7% versus 0.2% (P = 0.028, consistent with one 
extra event per 557 patient-years). After 1 year, of 
the five patients who had late thrombosis associ-
ated with sirolimus-eluting stents, two patients 
were taking aspirin and clopidogrel, two were tak-
ing only aspirin, and one was taking no antiplatelet 
agent. Of the nine patients with late thrombosis 
associated with paclitaxel-eluting stents, three 
were taking only aspirin, and five were taking no 
antiplatelet agent; the status of one patient is un-
known.
Revascularization
Both drug-eluting stents markedly reduced the 
rates of target-lesion revascularization and tar-
The New England Journal of Medicine 
Downloaded from nejm.org at LONDON SCH HYGIENE & TROPICAL MED on February 14, 2014. For personal use only. No other uses without permission. 
 Copyright © 2007 Massachusetts Medical Society. All rights reserved. 
Th e  n e w  e ng l a nd  j o u r na l  o f  m e dic i n e
n engl j med 356;10 www.nejm.org march 8, 20071002
get-vessel revascularization at 4 years (Table 3). 
The difference in the rates of clinical restenosis 
peaked at approximately 1 year and then remained 
stable through 4 years of follow-up (Fig. 1 and 
2). In the cohort of patients undergoing routine 
angiographic follow-up, both drug-eluting stents 
greatly reduced late luminal loss and binary re-
stenosis, as compared with bare-metal stents, both 
in-stent (within the stent margins) and in-seg-
ment (in-stent plus 5 mm proximal and distal mar-
gins) (see the Supplementary Appendix for de-
tails).
Death and Myocardial Infarction
The cumulative 4-year rate of death from any 
cause in the sirolimus-stent group did not differ 
significantly from that in the bare-metal–stent 
group (6.7% vs. 5.3%, P = 0.23); the difference in 
rates between the paclitaxel-stent group and the 
bare-metal–stent group was also not significant 
(6.1% vs. 6.6%, P = 0.68) (Table 3 and Fig. 1 and 2). 
Cumulative rates of death from any cause and 
from cardiac and noncardiac causes were also 
similar in both drug-eluting–stent groups and the 
bare-metal–stent group at 4 years (Table 3) and 
during each prespecified interval (Supplementary 
Appendix).
The cumulative 4-year rates of myocardial in-
farction were similar in the sirolimus-stent group 
and the bare-metal–stent group (6.4% vs. 6.2%, 
P = 0.86) and in the paclitaxel-stent group and 
the bare-metal–stent group (7.0% vs. 6.3%, P = 
0.66), with no significant differences in the rates 
of Q-wave or non–Q-wave myocardial infarction 
(Table 3 and Fig. 1 and 2). The rates of myocar-
dial infarction were also similar in both drug-
Table 2. Baseline Characteristics of the Patients.*
Variable
Sirolimus-Eluting 
Stent Bare-Metal Stent P Value
Paclitaxel-Eluting 
Stent Bare-Metal Stent P Value
Age — yr 61.9±11.1 61.9±10.7 0.91 62.4±10.8 62.2±10.6 0.49
Male sex — no./total no. (%) 629/878 (71.6) 622/870 (71.5) 0.96 1271/1755 (72.4) 1278/1758 (72.7) 0.88
Diabetes — no./total no. (%)
Any type 195/878 (22.2) 233/868 (26.8) 0.03 408/1755 (23.2) 419/1758 (23.8) 0.69
Requiring insulin 51/878 (5.8) 62/868 (7.1) 0.28 127/1729 (7.3) 138/1730 (8.0) 0.52
Hypertension — no./total  
no. (%)
557/873 (63.8) 548/866 (63.3) 0.84 1217/1755 (69.3) 1191/1754 (67.9) 0.36
Hyperlipidemia — no./total 
no. (%) 
613/866 (70.8) 617/859 (71.8) 0.67 1230/1744 (70.5) 1237/1751 (70.6) 0.94
Current smoker — no./ 
total no. (%)
183/862 (21.2) 210/858 (24.5) 0.12 413/1742 (23.7) 401/1749 (22.9) 0.60
Target coronary artery —  
no./total no. (%)
Left anterior descending  408/875 (46.6) 407/872 (46.7) 1.00 733/1744 (42.0) 730/1752 (41.7) 0.84
Left circumflex 181/875 (20.7) 181/872 (20.8) 1.00 444/1744 (25.5) 419/1752 (23.9) 0.31
Right coronary 254/875 (29.0) 254/872 (29.1) 1.00 560/1744 (32.1) 592/1752 (33.8) 0.30
Left main coronary 3/875 (0.3) 3/872 (0.3) 1.00 NA NA NA
Saphenous-vein graft 0/875 1/872 (<0.1) 0.50 NA NA NA
Reference vessel diameter — 
mm
2.72±0.45 2.72±0.48 0.98 2.74±0.51 2.74±0.51 0.83
Minimal luminal diameter — 
mm
0.94±0.37 0.93±0.36 0.50 0.91±0.35 0.91±0.37 0.58
Diameter stenosis — % 65.2±11.9 65.7±11.6 0.47 67.0±10.9 66.8±11.5 0.59
Lesion length — mm 13.8±5.7 13.9±5.9 0.96 15.1±7.9 15.1±8.0 0.88
No. of stents 1.42±0.69 1.39±0.61 0.38 1.21±0.48 1.19±0.46 0.19
Total stent length — mm 22.9±9.0 22.5±8.1 0.31 24.4±11.2 24.1±11.1 0.45
* Plus–minus values are means ±SD. NA denotes not applicable.
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eluting–stent groups and bare-metal–stent group 
at all prespecified time periods, except that there 
were significantly fewer myocardial infarctions 
in the paclitaxel-stent group than in the bare-
metal–stent group between 30 days after implan-
tation and 1 year (0.8% vs. 1.8%, P = 0.01).
There were no differences in the 4-year com-
posite rates of death or myocardial infarction, 
death or Q-wave myocardial infarction, or myo-
cardial infarction or death from cardiac causes 
between either drug-eluting stent and its control 
(Table 3) or at any interval time period (Supple-
mentary Appendix), except that between 30 days 
after implantation and 1 year, the composite rate 
of myocardial infarction or death from cardiac 
causes was lower in the paclitaxel-stent group 
than in the bare-metal–stent group (1.4% vs. 2.5%, 
P = 0.03). This reduction in rate was driven by a 
lower rate of non–Q-wave myocardial infarction 
in the paclitaxel-stent group than in the bare-
metal–stent group (0.4% vs. 1.6%, P<0.001).
Discussion
We performed a patient-level pooled meta-analy-
sis of four randomized, double-blind trials of siro-
limus-eluting stents versus bare-metal stents and 
five randomized, double-blind trials of paclitaxel-
eluting stents versus bare-metal stents in single, 
previously untreated coronary lesions through 
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time minus those with earlier events. The median duration of follow-up was 4.0 years.
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4 years of follow-up. The principal findings were 
that although the overall rates of stent thrombo-
sis were not significantly increased with drug-
eluting stents, both sirolimus-eluting stents and 
paclitaxel-eluting stents were associated with a 
small but significant increase in the incidence of 
late stent thrombosis between 1 and 4 years af-
ter implantation. In addition, both drug-eluting 
stents were associated with marked reductions 
in ischemic target-lesion revascularization and 
target-vessel revascularization, an advantage that 
was maintained through 4 years of follow-up. The 
rates of death or myocardial infarction were not 
significantly different between the groups with 
drug-eluting stents and the control groups, ei-
ther at 4 years of follow-up or between 1 and 
4 years.
The number of episodes of stent thrombosis 
within the first year were identical among pa-
tients with sirolimus-eluting stents and those with 
bare-metal stents (5 patients with episodes in each 
group) and among patients with paclitaxel-elut-
ing stents and those with bare-metal stents (12 
patients in each group). Between 1 and 4 years, 
however, there were modest increases in stent 
thrombosis in both groups with drug-eluting 
stents, as compared with the control groups (14 
patients with episodes in the groups with drug-
eluting stents vs. 2 patients in the bare-metal–
stent groups — a finding that is consistent with 
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approximately one extra stent thrombosis per 
500 patient-years of treatment with drug-eluting 
stents). Although our study does not identify the 
potential causes of late stent thrombosis, possible 
causes include delayed or incomplete endothe-
lialization, late polymer reactions, strut fractures, 
positive remodeling with stent malapposition with 
or without aneurysm formation, and new plaque 
rupture either adjacent to or within the stented 
site, among others.10-13,18,19
Our study also demonstrates a marked and 
persistent reduction in target-lesion revascular-
ization and target-vessel revascularization with 
both drug-eluting stents, as compared with bare-
metal stents. The maximal difference between 
drug-eluting stents and bare-metal stents in clini-
cal restenosis occurred by 1 year, with the hazard 
curves remaining parallel between 1 and 4 years. 
In this regard, the durability of clinical efficacy 
for drug-eluting stents during late follow-up stands 
in contradistinction to the “catch-up” phenomenon 
of late restenosis noted after coronary brachy-
therapy.20,21 Although the performance of routine 
angiographic follow-up may have increased the 
absolute difference in the rates of clinical reste-
nosis between drug-eluting stents and bare-metal 
stents, the relative benefit is unlikely to have been 
affected.22
No significant differences in the cumulative 
4-year rates of death or myocardial infarction were 
observed between patients receiving either drug-
eluting stents or bare-metal stents. It is possible 
that reductions in the rates of death or myocar-
dial infarction that otherwise might result from 
prevention of restenosis by drug-eluting stents 
may be offset by adverse events resulting from 
late stent thrombosis. In-stent restenosis pre-
sents as acute myocardial infarction in 3.5 to 19.4% 
of patients23-26 and as such is not always a benign 
process. However, the majority of episodes of 
stent thrombosis present as death or myocardial 
infarction.27,28 Thus, a large reduction in a phe-
nomenon with moderate clinical risk (resteno-
sis) may be offset by a small increase in a phenom-
enon with high clinical risk (stent thrombosis).
It is important to note that stent thromboses 
occurring subsequent to any target-lesion revas-
cularization were excluded from the counts of 
episodes of stent thrombosis in most of the tri-
als (see the definitions of stent thrombosis in the 
Supplementary Appendix).29 The purpose of this 
exclusion was to ensure that only episodes of 
stent thrombosis related to the original stent 
were included. However, the procedures to treat 
restenosis (balloon angioplasty, brachytherapy, 
or additional stenting) may result in “secondary” 
episodes of stent thrombosis. Such secondary 
stent thromboses would be expected to be more 
common with bare-metal stents, since revascu-
larization procedures are much more common with 
these stents. Indeed, in an unpublished analysis, 
when such secondary episodes were considered, 
no overall or late differences in the patient-level 
rates of stent thrombosis between drug-eluting 
stents and bare-metal stents were present.29 Since 
data regarding death and myocardial infarction 
were not censored after target-lesion revascular-
ization, greater rates of restenosis and secondary 
thrombosis with bare-metal stents than with drug-
eluting stents probably contributed to the similar 
observed overall rates of death and myocardial 
infarction between the stent types in our analysis. 
Given the difficulties in defining stent thrombosis 
in the absence of angiographic confirmation or 
results on autopsy, greater emphasis should be 
placed on the occurrence of death and myocardial 
infarction, in our opinion, rather than on stent 
thrombosis, as indicative of the overall safety pro-
file of a coronary intervention. Moreover, given the 
observation that the directional effect of drug-elut-
ing stents on subsequent stent thrombosis, revas-
cularization, death, and myocardial infarction may 
vary, we believe that composite measures com-
bining safety and efficacy end points should be 
avoided in future trials of antirestenotic devices.
Our findings differ from those of some other 
investigators, who have suggested, on the basis 
of trial-level meta-analyses, that overall rates of 
stent thrombosis and death are higher with drug-
eluting stents than with bare-metal stents.16,17 
These discrepancies may be partially explained 
by the fact that we had access to the complete 
patient-level data from the trials we examined and 
did not have to rely on an estimation of event rates 
from limited published results, abstracts, and 
online summaries. We also confined our analysis 
to a precisely defined subgroup of clinical trials 
involving drug-eluting stents, whereas some previ-
ous analyses have also included later studies that 
were not double-blind.16
Several limitations of our analysis deserve com-
ment. First, given the relatively infrequent occur-
rence of death, myocardial infarction, and stent 
thrombosis, larger studies with longer-term fol-
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low-up are required to detect small differences in 
event rates. Moreover, we made no adjustments 
for the multiple end points examined. The inter-
val data analyses in particular should be consid-
ered hypothesis-generating. Second, our analysis 
is most applicable for patients with single, previ-
ously untreated coronary lesions, as reflected in 
the labels for sirolimus-eluting stents (lesions as 
long as 30 mm in vessels of 2.5 to 3.5 mm in di-
ameter) and paclitaxel-eluting stents (lesions as 
long as 28 mm in vessels of 2.5 to 3.75 mm in 
diameter) that were approved by the Food and 
Drug Administration. The rates of stent throm-
bosis and the relative risk–benefit ratio of drug-
eluting stents versus bare-metal stents may vary 
in the “real world,” in which stents are implanted 
in more complex scenarios (i.e., “off-label” use).27,28 
Third, the nine studies we analyzed used differ-
ent clinical sites, adjudication committees, and 
core laboratories, with possible differences in 
definitions and processes. Fourth, the paclitaxel-
stent trials included both the commercial slow 
rate–release formulation and the noncommercial-
ized moderate rate–release formulation. Howev-
er, the results were directionally similar with both 
devices, and no major differences have been de-
scribed between the two versions of this stent.6 
Fifth, in five of the trials, the protocol-specified 
definitions of stent thrombosis after 30 days re-
quired angiographic confirmation and may there-
fore underestimate the true event rate. Sixth, pool-
ing of the data from sirolimus-stent trials and 
paclitaxel-stent trials was avoided, since the mech-
anisms underlying the safety and efficacy of these 
two types of stents may differ. Given the differ-
ent entry criteria for types of lesions in the two 
groups of trials, as well as the different bare-
metal stents used as controls, comparisons across 
the two pooled meta-analyses may not be valid. 
Finally, detailed data regarding the use of anti-
platelet medication throughout the follow-up pe-
riod were not available, precluding firm recom-
mendations regarding the optimal duration of 
thienopyridine administration.
In conclusion, our study examined the relative 
safety and efficacy of drug-eluting stents, as com-
pared with bare-metal stents, in a pooled, patient-
level analysis of double-blind, randomized trial 
data. The use of both sirolimus-eluting stents and 
paclitaxel-eluting stents was associated with a 
small but significant increase in the incidence of 
late stent thrombosis between 1 and 4 years after 
implantation, as compared with that of bare-metal 
stents. We also reconfirmed the marked benefit 
of both types of drug-eluting stents in reducing 
the need for subsequent revascularization pro-
cedures, with persistence of this benefit through 
4 years of follow-up. We found no significant dif-
ferences between drug-eluting stents and bare-
metal stents in the rates of death or myocardial 
infarction.
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